相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PGC1β Mediates PPARγ Activation of Osteoclastogenesis and Rosiglitazone-Induced Bone Loss
Wei Wei et al.
CELL METABOLISM (2010)
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
R. E. Aubert et al.
DIABETES OBESITY & METABOLISM (2010)
Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis
B. Gustafson et al.
DIABETOLOGIA (2010)
The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study
F. -Y. Hsiao et al.
DIABETOLOGIA (2010)
Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss
Laura E. Targownik et al.
GASTROENTEROLOGY (2010)
The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes
Hong Li et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2010)
Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes
Dori Bilik et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus
Zeina A. Habib et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Management of glucocorticoid-induced osteoporosis
Juliet Compston
NATURE REVIEWS RHEUMATOLOGY (2010)
Pioglitazone and mechanisms of CV protection
E. Erdmann et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
Thiazolidinediones and Fractures in Men and Women
Colin R. Dormuth et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Vertebral fractures in males with type 2 diabetes treated with rosiglitazone
Tatiana Mancini et al.
BONE (2009)
Thiazolidinedione use and the risk of fractures
Konstantinos A. Toulis et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
G. Schernthaner
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
Daniel H. Solomon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPAR gamma agonist pioglitazone
Unni Syversen et al.
BMC ENDOCRINE DISORDERS (2009)
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Ian J. Douglas et al.
PLOS MEDICINE (2009)
Use of thiazolidinediones and fracture risk
Christian Meier et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture
Peter Vestergaard et al.
CALCIFIED TISSUE INTERNATIONAL (2008)
Use of proton pump inhibitors and risk of osteoporosisrelated fractures
Laura E. Targownik et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2008)
Osteoporosis among patients with type 1 and type 2 diabetes
A. Raekel et al.
DIABETES & METABOLISM (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Exposure to antiepileptic drugs and the risk of hip fracture: A case-control study
Ioannis Tsiropoulos et al.
EPILEPSIA (2008)
Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression
Lana J. Williams et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Fracture risk in type 2 diabetes: Update of a population-based study
L. Joseph I. I. I. I. Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial
Dorte Glintborg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy
A. M. Pack et al.
NEUROLOGY (2008)
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors
James A. Kaye et al.
PHARMACOTHERAPY (2008)
Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy
Merete Alice Lyngstad-Brechan et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2008)
Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients A case-control study
Matteo Monami et al.
DIABETES CARE (2008)
Skeletal consequences of thiazolidinedione therapy
A. Grey
OSTEOPOROSIS INTERNATIONAL (2008)
PPAR-γ regulates osteoclastogenesis in mice
Yihong Wan et al.
NATURE MEDICINE (2007)
Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis
Selculk Dagdelen et al.
ADVANCES IN THERAPY (2007)
Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women
Zehra Berberoglu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Use of antidepressants and rates of hip bone loss in older women
Susan J. Diem et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men
Elizabeth M. Haney et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone
Oxana P. Lazarenko et al.
ENDOCRINOLOGY (2007)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Effect of selective serotonin reuptake inhibitors on the risk of fracture
J. Brent Richards et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men
Subhashini Yaturu et al.
DIABETES CARE (2007)
Long-term proton pump inhibitor therapy and risk of hip fracture
Yu-Xiao Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study
Denise E. Bonds et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Thiazolidinedione use and bone loss in older diabetic adults
Ann V. Schwartz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture
P. Vestergaard et al.
CALCIFIED TISSUE INTERNATIONAL (2006)
Use of antiepileptic drugs and risk of fractures - Case-control study among patients with epilepsy
PC Souverein et al.
NEUROLOGY (2006)
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA)
ES Siris et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Risk of osteoporotic fracture in elderly patients taking warfarin - Results from the National Registry of Atrial Fibrillation 2
BF Gage et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation
AA Ali et al.
ENDOCRINOLOGY (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women - The fracture intervention trial
THM Keegan et al.
DIABETES CARE (2004)
Bone is a target for the antidiabetic compound rosiglitazone
SO Rzonca et al.
ENDOCRINOLOGY (2004)
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
MA Sorocéanu et al.
JOURNAL OF ENDOCRINOLOGY (2004)
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone)
V Sottile et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow
CA Gregory et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis
TP van Staa et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
MR Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Use of oral corticosteroids and risk of fractures
TP Van Staa et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
分享论文
